Lonza Group AG LONN
SIX · Switzerland · Health Technology
CHF 560.60-14.60 (-2.54%)
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Gene Transfer Technologies Market Size, Share & Trends Analysis - Global Opportunity Analysis and Industry Forecast (2026-2036)" has been added to ResearchAndMarkets.com's offering.The global Gene Transfer Technologies Market is projected to witness robust growth during the forecast period from 2026 to 2036, driven by the rapid expansion of gene and cell therapies, increasing investments in genomic medicine, and continuous advancements in vector engine
Europe’s cell therapy sector is shifting to closed, automated systems, creating opportunities in AI monitoring, modular scale-up, CAR-T/ATMP production and decentralized manufacturingDublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Europe Automated and Closed Cell Therapy Processing Systems Market Size, Share & Industry Analysis Report by Type, Scale, Workflow, Country Outlook and Forecast, 2026-2033" has been added to ResearchAndMarkets.com's offering. The Europe automated and closed cell therapy pr
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.